Adlai Nortye Ltd. (ANL)
NASDAQ: ANL · Real-Time Price · USD
1.560
+0.050 (3.31%)
At close: Nov 14, 2025, 4:00 PM EST
1.525
-0.035 (-2.24%)
After-hours: Nov 14, 2025, 7:37 PM EST
Adlai Nortye Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
123
Market Cap
57.56M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 45.73M | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ANL News
- 4 weeks ago - Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
- 1 year ago - Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024 - GlobeNewsWire
- 1 year ago - Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy - GlobeNewsWire
- 1 year ago - Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development - GlobeNewsWire
- 2 years ago - Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC - GlobeNewsWire
- 2 years ago - Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award - GlobeNewsWire
- 2 years ago - Adlai Nortye Dives In Nasdaq Debut, As Key Product Faces Hurdles - Seeking Alpha
- 2 years ago - Adlai Nortye Ltd. Announces Closing of Initial Public Offering - GlobeNewsWire